Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

YOU WONT BELIEVE: Amylyx pharmaceuticals | Mind Blowing Facts

Amylyx Halts Rare Brain Disorder Drug Program After Disappointing Trial

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) on Wednesday decided to discontinue the ORION program of AMX0035 (sodium phenylbutyrate [PB] and taurursodiol [TURSO, also known as ursodoxicoltaurine]) in adults living with progressive supranuclear palsy (PSP).

This Amylyx Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday

This Amylyx Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Lots of drug companies talk about putting patients first — but this one actually did

Lots of drug companies talk about putting patients first — but this one actually did

When Amylyx Pharmaceuticals found out its ALS drug Relyvrio didn't work, the company took the unusual step of voluntarily pulling it off the market.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Amylyx Pharmaceuticals Withdraws ALS Drug Relyvrio From Market

Amylyx Pharmaceuticals withdraws Relyvrio drug for ALS due to lack of efficacy, leading to layoffs and disappointment in ALS community.

Markets Today: Signs of Progress in Debt Ceiling Talks Boost Stocks

Morning Markets June E-Mini S&P 500 futures (ESM2 3) this morning are up +0.28%, and June Nasdaq 100 E-Mini futures (NQM2 3) are up +0.12%. U.S. stock index futures this morning are moderately higher. Signs of progress on a deal to raise the debt ceiling are lifting stock index futures...

Amylyx Pharmaceuticals Shares Shoot Up As FDA Extends Review Of NDA For Neurodegenerative Disease Candidate

The U.S. Food and Drug Administration (FDA) has extended the review of New Drug Application (NDA) by three months, submitted by Amylyx Pharmaceuticals (NASDAQ: AMLX) for its lead drug candidate AMX0035 with regard to the treatment of patients with amyotrophic lateral sclerosis (ALS).

Here's Why Amylyx Pharmaceuticals Shares Are Skyrocketing Today

Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) shares are trading higher by 37.67% at $13.45 after the company announced the FDA extended the review timeline of the New Drug Application for AMX0035.

inkl

Read news from The Economist, FT, and more,
with one subscription

Expert Ratings For Amylyx Pharmaceuticals

Expert Ratings For Amylyx Pharmaceuticals

Within the last quarter, Amylyx Pharmaceuticals (NASDAQ:AMLX) has observed the following analyst ratings:

Commentary: FDA shouldn’t approve ALS drug without more data

A panel of the Food and Drug Administration’s expert advisers on Wednesday voted 6 to 4 against approving Amylyx Pharmaceuticals’ treatment for ALS. The FDA now has until June 29 to decide whether to follow the panel’s advice or let the closely watched drug on to the market.

Tribune News Service

Stocks That Hit 52-Week Lows On Monday

Stocks That Hit 52-Week Lows On Monday

On Monday, 147 stocks hit new 52-week lows.

1

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Food and Drug Administration

Governing Council

Mizuho Securities

Wells Fargo Securities

Amylyx Pharmaceuticals

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Amyotrophic lateral sclerosis

Places

364,519 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play